Healthcare

Eli Lilly (NYSE: LLY) has agreed to acquire AtaiBeckley in a deal valued at approximately $2.8 billion, marking one of the most significant pharmaceutical transactions focused on psychedelic-derived medicines.

Raphael Pharmaceutical has restructured its leadership team, bringing in a new chief financial officer while two key executives exit. The changes, announced in regulatory filings, reflect ongoing adjustments in the company’s governance as it works through operational and strategic priorities.

The rally lifted the company’s market capitalization to $2.0 billion, capping a month of aggressive gains that have outpaced broader sector moves. For investors, the breakout raises questions about whether the momentum can sustain itself, or if the stock is due for a pullback …

Proceeds are earmarked for working capital and general corporate purposes, a sign of urgency as the stock has shed 72.1% year-to-date. With a market cap of only $2 million, the deal’s size, equivalent to 200% of that value, highlights the company’s precarious financial position …

Polaryx Therapeutics (NASDAQ: PLYX) announced that its upcoming annual meeting of shareholders will be conducted virtually in September, and that shareholders recorded as owners on the designated record date will receive notice and voting rights. This approach follows a postponed meeting in the prior …

DBV Technologies has reported a decline in operating income as it intensifies investments in clinical development and commercial preparations for its Viaskin Peanut Patch, a potential treatment for peanut allergies in children. The company disclosed $0.7 million in operating income for the quarter ending …

Encompass Health (NYSE: EHC) is attracting investor attention as its shares remain near recent highs, even as broader small-cap momentum shows signs of cooling. The company’s stock has demonstrated resilience in recent weeks, though it experienced a minor pullback in recent trading. Institutional investors …